Potential breakthrough therapy for uterine fibroids and endometriosis.
Protected by two US patents (10,251,836 and 11,116,718).Clinical efficacy testing starts with Phase IIb.
Optimal use of the most promising drug: ultra-low doses of a specific Selective Progesterone Receptor Modulator (SPRM) are delivered by a novel route, directly to affected tissues:
Greater Efficacy: High local drug concentrations result in strong therapeutic action at a small fraction of oral dose – superior to other therapies.
Limited Side Effects: Unlike other hormonal therapies (e.g., Lupron Depot®), Premring will NOT be associated with severe menopausal symptoms, such as hot flashes and bone loss.
Safe Long-Term Therapy: Improved safety permits long-term treatment (not an option for other hormonal medications), greatly reducing the need for hospitalizations and radical surgeries.